Table S1 Univariable analysis of the relationship between HIV-related variables and plaque prevalence

Variables	Total plaque prevalence		Calcified plaque prevalence		Noncalcified plaque prevalence	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
CD4 current						
>700			Reference			
350–700	0.882 (0.434–1.793)	0.73	0.658 (0.297–1.454)	0.30	1.606 (0.735–3.506)	0.24
<350	1.190 (0.400–3.544)	0.75	1.143 (0.357–3.660)	0.82	1.803 (0.569–5.716)	0.32
CD4 nadir						
>350			Reference			
200–350	1.003 (0.445–2.262)	>0.99	0.465 (0.176–1.231)	0.12	1.794 (0.718–5.482)	0.21
100–199	1.929 (0.748–4.972)	0.17	1.496 (0.551–4.056)	0.43	2.187 (0.769–6.216)	0.14
<100	2.700 (0.990–7.364)	0.05	1.368 (0.480–3.898)	0.56	4.407 (1.519–12.786)	0.006*
CD4/CD8						
>1.0			Reference			
0.5–1.0	0.649 (0.303–1.390)	0.27	0.635 (0.269–1.499)	0.30	1.137 (0.497–2.600)	0.76
<0.5	1.299 (0.572–2.947)	0.53	0.958 (0.390–2.351)	0.93	2.092 (0.878–4.986)	0.10
Time of HIV diagnosis (years)						
<5			Reference			
5–10	1.008 (0.476–2.132)	0.98	0.862 (0.368–2.015)	0.73	1.299 (0.582–2.898)	0.52
>10	1.071 (0.470–2.440)	0.87	1.010 (0.403–2.532)	0.98	1.388 (0.579–3.327)	0.46
Time of ART use (years)						
<5			Reference			
5–10	0.782 (0.387–1.578)	0.49	0.678 (0.304–1.510)	0.34	1.015 (0.478–2.152)	0.97
>10	1.804 (0.711–4.576)	0.21	1.250 (0.465–3.358)	0.66	2.130 (0.827–5.485)	0.12
ART regimens						
2 NRTI + 1 NNRTI			Reference			
2 NRTI + 1 PI	1.245 (0.409–3.789)	0.70	1.117 (0.325–3.840)	0.86	1.542 (0.498–4.777)	0.45
Others	0.917 (0.418–2.013)	0.83	0.894 (0.363–2.203)	0.81	1.028 (0.450–2.348)	0.95

*, P<0.05. HIV, human immunodeficiency virus; OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy; NTRI, nucleoside reverse transcriptase inhibitor; NNTRI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.